Careers
Contact
India flag iconIndiaUSA flag iconUSAGreat Britain flag iconUKSouth Africa flag iconSouth AfricaAustralia flag iconAustraliaPhilippines flag iconPhilippinesGermany flag iconGermanyNetherlands flag iconNetherlandsMexico flag iconMexicoBrazil flag iconBrazilCanada flag iconCanadaSwitzerland flag iconSwitzerland
Integrated Annual Report - Lupin
Integrated Annual Report - Lupin
ShareholderInformation
Stock Exchange IntimationsAGM, Postal Ballot, and EGMShareholding PatternShare PriceRatingsDividendUnclaimed Dividend and SharesEmployee Stock Option SchemesImportant Communication for ShareholdersInvestor FAQsInvestor Contacts

Stock Exchange Intimations

Search
Schedule of Analyst Institutional Investors MeetLupin Receives U.S. FDA Approval for Modafinil Tablets, USPESG Rating by Crisil ESG Ratings and Analytics LtdAllotment of Shares pursuant to ESOPESG Rating by ESG Risk Assessments and Insights LimitedVISUfarma B.V., The Netherlands Enters into an Exclusive License Agreement with Visus Therapeutics, Inc. U.S.A.Demise Intimation of Senior Management PersonnelLupin Announces Approval from U.S. FDA for Pitolisant TabletsTranscript - Q1 FY27 Earnings Conference CallLupin Announces the Approval of Sodium Zirconium Cyclosilicate for Oral Suspension in the United States
Product Finder
Stock Exchange Intimations - Shareholder Information | Lupin